David Schenkein has been a hematologist and medical oncologist for more than 20 years. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center and is a member of the board of directors for the Biotechnology Industry Organization, the world’s largest biotechnology trade association, a position he has held since 2012. Prior to joining Agios as CEO in 2009, he was the senior vice president, clinical hematology/oncology, at Genentech, Inc., where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Earlier he served as senior vice president of clinical research at Millennium Pharmaceuticals, overseeing the clinical development and worldwide approval of the cancer therapy Velcade. Schenkein holds a BA in chemistry from Wesleyan University and an MD from the State University of New York Upstate Medical School. Twitter: @schenkein